NasdaqGS - Delayed Quote • USD
AstraZeneca PLC (AZN)
At close: April 26 at 4:00 PM EDT
After hours: April 26 at 7:45 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 3 | 3 | 6 | 6 |
| Avg. Estimate | 1.32 | 1.43 | 4.54 | 5.12 |
| Low Estimate | 0.99 | 1.02 | 3.06 | 3.52 |
| High Estimate | 1.88 | 2.13 | 7.98 | 8.86 |
| Year Ago EPS | 1.08 | 0.87 | 3.63 | 4.54 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 3 | 3 | 9 | 9 |
| Avg. Estimate | 12.52B | 12.87B | 51.07B | 55.16B |
| Low Estimate | 12.36B | 12.68B | 49.85B | 52.45B |
| High Estimate | 12.7B | 13B | 52.4B | 59.2B |
| Year Ago Sales | 10.96B | 11.55B | 45.81B | 51.07B |
| Sales Growth (year/est) | 14.20% | 11.40% | 11.50% | 8.00% |
Earnings History
| CURRENCY IN USD | 6/30/2023 | 9/30/2023 | 12/31/2023 | 3/31/2024 |
|---|---|---|---|---|
| EPS Est. | 0.95 | 0.84 | 0.79 | 1.22 |
| EPS Actual | 1.08 | 0.87 | 0.72 | 1.03 |
| Difference | 0.13 | 0.03 | -0.07 | -0.19 |
| Surprise % | 13.70% | 3.60% | -8.90% | -15.60% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | 1.32 | 1.43 | 4.54 | 5.12 |
| 7 Days Ago | 1.32 | 1.43 | 4.56 | 5.13 |
| 30 Days Ago | 1.34 | 1.45 | 3.89 | 4.39 |
| 60 Days Ago | 1.35 | 1.45 | 4.94 | 5.64 |
| 90 Days Ago | 1.24 | 1.3 | 4.28 | 5.01 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | 1 |
| Up Last 30 Days | -- | -- | 2 | 2 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | 1 | 1 |
Growth Estimates
| CURRENCY IN USD | AZN | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 22.20% | -- | -- | 6.50% |
| Next Qtr. | 64.40% | -- | -- | 12.00% |
| Current Year | 25.10% | -- | -- | 5.30% |
| Next Year | 12.80% | -- | -- | 13.10% |
| Next 5 Years (per annum) | 13.20% | -- | -- | 11.09% |
| Past 5 Years (per annum) | 16.82% | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Maintains | BMO Capital: Outperform to Outperform | 4/26/2024 |
| Upgrade | Deutsche Bank: Sell to Hold | 4/16/2024 |
| Maintains | BMO Capital: Outperform to Outperform | 2/12/2024 |
| Downgrade | Deutsche Bank: Buy to Hold | 2/8/2024 |
| Initiated | Morgan Stanley: Overweight | 1/23/2024 |
| Downgrade | Jefferies: Buy to Hold | 1/3/2024 |
Related Tickers
SNY Sanofi
49.13
-0.47%
MRK Merck & Co., Inc.
131.20
+0.37%
BMY Bristol-Myers Squibb Company
44.85
+0.34%
NVS Novartis AG
97.44
-1.64%
GILD Gilead Sciences, Inc.
65.42
+0.23%
BIIB Biogen Inc.
208.90
+3.18%
GSK GSK plc
41.11
+0.49%
PFE Pfizer Inc.
25.40
+0.55%
ABBV AbbVie Inc.
159.62
-4.58%
LLY Eli Lilly and Company
733.51
+1.19%